Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Anavex Life Sciences to Present at the B. Riley Securities' Virtual Neuroscience Conference

GlobeNewswire April 26, 2021

Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome

GlobeNewswire April 12, 2021

Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 8, 2021

Anavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021

GlobeNewswire April 7, 2021

Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer's Disease

GlobeNewswire March 31, 2021

Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled "Future Avenues for Alzheimer's Disease Detection and Therapy"

GlobeNewswire March 16, 2021

Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 4, 2021

Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®

GlobeNewswire February 22, 2021

Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit

GlobeNewswire February 19, 2021

Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021

GlobeNewswire February 18, 2021

Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook

GlobeNewswire February 11, 2021

Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021

GlobeNewswire February 8, 2021

Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson's Disease

GlobeNewswire January 11, 2021

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference

GlobeNewswire January 6, 2021

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

GlobeNewswire December 28, 2020

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020

GlobeNewswire December 22, 2020

Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.

GlobeNewswire December 21, 2020

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

GlobeNewswire December 15, 2020

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders

GlobeNewswire November 30, 2020

Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

GlobeNewswire November 25, 2020